CTIM-13. CLINICAL EFFICACY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, IN RECURRENT GBM DELIVERED BY CONVECTION ENHANCED DELIVERY (CED)

BACKGROUND: MDNA55 is an IL4R-targeted toxin in development for GBM, a universally fatal disease. IL4R is over-expressed in GBM, the tumor microenvironment, and high expression is associated with poor outcomes in GBM. METHOD: MDNA55-05 is an open-label, single-arm study of MDNA55 delivered by CED as...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Sampson, John, Achrol, Achal, Aghi, Manish, Bankiewiecz, Krystof, Bexon, Martin, Brem, Steven, Brenner, Andrew, Chandhasin, Chandtip, Chowdhary, Sajeel, Coello, Melissa, Ellingson, Benjamin, Floyd, John, Han, Seunggu, Kesari, Santosh, Merchant, Fahar, Merchant, Nina, Randazzo, Dina, Vogelbaum, Michael, Vrionis, Frank, Zabek, Miroslaw, Butowski, Nicholas
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2020
נושאים:
Clinical Trials: Immunologic
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650324/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.147
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים